This document summarizes the results of the German Aortic Valve Registry (GARY) which collected data on 13,860 patients undergoing either conventional surgery or catheter-based procedures for aortic valve disease in 2011. The registry included data on 6,523 patients who underwent conventional aortic valve replacement without coronary bypass surgery (AVR), 3,464 who underwent AVR with coronary bypass surgery (AVR+CABG), 2,695 who underwent transvascular catheter-based aortic valve implantation (TAVI), and 1,181 who underwent transapical TAVI. Patients who underwent catheter-based procedures were significantly older and had higher risk profiles. The in-hospital stroke rates were low across all groups. In-
Presentación "Estenosis aórtica riesgo moderado" del Lino Patricio durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Update de los estudios de ABSORB hasta 2014" del Dr. Flavio Ribichini durante la Mesa Redonda sobre Scaffolds reabsorbibles de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
A randomised comparison of reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents in patients with diabetes mellitus: the RESERVOIR clinical trial
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
Novedades en farmacología en intervencionismo
Antonio Fernández Ortiz (Hosp. Clínico San Carlos. Madrid)
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Estenosis aórtica riesgo moderado" del Lino Patricio durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Update de los estudios de ABSORB hasta 2014" del Dr. Flavio Ribichini durante la Mesa Redonda sobre Scaffolds reabsorbibles de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
A randomised comparison of reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents in patients with diabetes mellitus: the RESERVOIR clinical trial
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
Novedades en farmacología en intervencionismo
Antonio Fernández Ortiz (Hosp. Clínico San Carlos. Madrid)
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
Aportaciones del grupo CORPAL en intervencionismo coronario
Alfonso Medina Fernández-Aceytuno (Hosp. Univ. Doctor Negrín. Las Palmas de Gran Canaria)
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
TORO. Registro Español de Oclusión Crónica total secundaria a restenosis oclusiva intrastent
José R. Rumoroso
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
REPARA. Registro de paciEntes con dispositivo biorreabsorbible en la Práctica clínica habitual
Impact of access site on bleeding and ischemic events in patients with non-ST-segment elevation myocardial infarction treated with prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis: the ACCOAST access substudy
Safety and efficacy of using a single transradial MAC guiding catheter for coronary angiography and intervention in patients with ST-elevation myocardial infarction (RAPID)
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
¿Qué entendemos por corazón normal y cuáles son los mecanismos?
La TV idiopática es una anomalía eléctrica sin cardiopatía estructural de pronóstico habitualmente benigno.
Los medios habituales de diagnóstico de cardiopatía son suficientes en la mayoría de los casos.
Trabajo "Coronaria descendente anterior con morfología en “y”: Una rara anomalía coronaria" premiado en la categoría Imagen en la XXV Reunión Anual de la SHCI de 2014 en Córdoba.
Autores: Javier Cuesta, Fernando Rivero, Teresa Bastante,
Amparo Benedicto y Fernando Alfonso del Hospital Universitario de La Princesa de Madrid (España).
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
Aportaciones del grupo CORPAL en intervencionismo coronario
Alfonso Medina Fernández-Aceytuno (Hosp. Univ. Doctor Negrín. Las Palmas de Gran Canaria)
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
TORO. Registro Español de Oclusión Crónica total secundaria a restenosis oclusiva intrastent
José R. Rumoroso
XXVII Reunión anual de la sección de Hemodinámica y Cardiología Intervencionista
16 y 17 de junio de 2016 León
http://secardiologia.es/xxvii-reunion-anual-de-la-seccion-de-hemodinamica-y-cardiologia-intervencionista
REPARA. Registro de paciEntes con dispositivo biorreabsorbible en la Práctica clínica habitual
Impact of access site on bleeding and ischemic events in patients with non-ST-segment elevation myocardial infarction treated with prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis: the ACCOAST access substudy
Safety and efficacy of using a single transradial MAC guiding catheter for coronary angiography and intervention in patients with ST-elevation myocardial infarction (RAPID)
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
¿Qué entendemos por corazón normal y cuáles son los mecanismos?
La TV idiopática es una anomalía eléctrica sin cardiopatía estructural de pronóstico habitualmente benigno.
Los medios habituales de diagnóstico de cardiopatía son suficientes en la mayoría de los casos.
Trabajo "Coronaria descendente anterior con morfología en “y”: Una rara anomalía coronaria" premiado en la categoría Imagen en la XXV Reunión Anual de la SHCI de 2014 en Córdoba.
Autores: Javier Cuesta, Fernando Rivero, Teresa Bastante,
Amparo Benedicto y Fernando Alfonso del Hospital Universitario de La Princesa de Madrid (España).
Presentación "Redes de infarto: Utilización para trombolisis precoz" del Dr. José A. Barrabés durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Trabajo " Oclusión Crónica de 2 vasos: Cuando la apertura de una arteria te muestra el camino para abordar la segunda" premiado en la categoría Casos CTO en la XXV Reunión Anual de la SHCI de 2014 en Córdoba.
Autores: Soledad Ojeda, Manuel Pan, Miguel Romero, Javier Suárez de Lezo, Francisco Mazuelos, José Segura y José Suárez de Lezo del Servicio de Cardiología. H. U. Reina Sofía de Córdoba (España).
Participación del Dr. José Suárez de Lezo durante la Mesa Redonda sobre Scaffolds reabsorbibles de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Intervención Coronaria" del Dr. Javier Soriano durante la Mesa Redonda "Novedades en cardiología Intervencionista del último Congreso a este" de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Pautas cortas de doble antiagregación tras intervencionismo coronario: pros y contras" del Dr. Esteban López de Sá durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Novedades en farmacología para el cardiólogo intervencionista" del Dr. José Antonio Baz Alonso durante la Mesa Redonda "Novedades en cardiología Intervencionista del último Congreso a este" de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Estenosis aórtica riesgo moderado: Cirugía" del Dr. Alberto Forteza durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Experiencia preliminar con el ABSORB en lesiones off-label. Eficacia y seguridad del dispositivo" del Dr. Manuel Pan Álvarez-Osorio durante la Mesa Redonda sobre Scaffolds reabsorbibles de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Repara. Presentación del Registro y Situación actual" del Dr. Felipe Hernández durante la Mesa Redonda sobre Scaffolds reabsorbibles de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Foramen Oval Permeable e Ictus: Tratamiento médico" del Dr. Joaquín Serena durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Miembros inferiores" del Dr. José Urbano durante el Taller de Intervencionismo Periférico de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Foramen Oval Permeable e Ictus: Tratamiento percutáneo" del Dr. Javier Goicolea durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
DETAILS OF EVIDENCE TAVI FROM ITS EXISTENCE IN INTERVENTIONAL CARDIOLOGY TO THE SURTAVI REGISTRY ..AS AN OPTION FROM HIGH RISK UNOPERABLE PATIENTS TO INTERMEDIATE AND LOW RISK PATIENTS
A US Food and Drug Administration advisory panel voted 7 to 5 in favor of approving a device for closure of the left atrial appendage (LAA) as an alternative to long-term warfarin therapy for the prevention of stroke in warfarin-eligible patients with nonvalvular atrial fibrillation (AF).
Fundación EPIC _ Sedación anestesia general y eco de guiadoFundacion EPIC
Presentación de la ponencia "Sedación anestesia general y eco de guiado" por el Doctor Moris de la Tasa en los Diálogos EPIC_Retos Clínicos en Válvulas Transcatéter/ Clinical Challenges in TAVR today, el 10 de Mayo de 2018 en Barcelona (España)
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
4. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Efecto placebo al ser incluido y mayor adherencia
a la medicación
Porcentaje mayor de antialdosterónicos
Sesgo en estudios previos al conocerse el grupo
asignado
¿Efectiva sólo en hiperactividad simpática?
Catéter monopolar
DENERVACIÓN RENAL
7. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Final Results of the EVEREST
Controlled Trial of Percutane
Reduction of Mitral Reg
Ted Feldman, MD, FACC, F
on behalf of the EVEREST II I
ACC 2014
Washington, DC
Kaplan-Meier Freedom From Mortality
EVEREST II RCT
Baseline 6 Months 12 Months 18 Months 2 Years 3 Years 4 Years 5 Years
MitraClip # At Risk 178 165 158 154 143 133 119 58
Surgery # At Risk 80 76 70 70 65 57 52 24
93.7%
92.3%
1 year
81.2%
79.0%
5 years
MitraClip (N=178)
Surgery (N=80)
PML04247 Rev. A
Kaplan-Meier Freedom From Mortality
EVEREST II RCT
MitraClip (N=178)
INSUFIENCIA MITRAL
8. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Baseline 6 Months 12 Months 18 Months 2 Years 3 Years 4 Years 5 Years
MitraClip # At Risk 178 136 128 125 117 109 98 45
Surgery # At Risk 80 75 69 68 63 54 49 21
78.9%
97.4%
1 year 74.3%
92.5%
5 years
MitraClip (N=178)
Surgery (N=80)
Kaplan-Meier Freedom From MV Surgery in
MitraClip Group or Re-operation in Surgery Group
EVEREST II RCT
PML04247 Rev. A
78.9%
97.4%
1 year 74.3%
92.5%
5 years
MitraClip (N=178)
Surgery (N=80)
Kaplan-Meier Freedom From MV Surgery in
MitraClip Group or Re-operation in Surgery Group
Final Results of the EVEREST
Controlled Trial of Percutane
Reduction of Mitral Reg
Ted Feldman, MD, FACC, F
on behalf of the EVEREST II I
ACC 2014
Washington, DC
INSUFIENCIA MITRAL
9. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Final Results of the EVEREST
Controlled Trial of Percutane
Reduction of Mitral Reg
Ted Feldman, MD, FACC, F
on behalf of the EVEREST II I
ACC 2014
Washington, DC
Mitral Regurgitation Grade
EVEREST II RCT All Treated Patients (N=258)
MitraClip (N=178)
2+
4+
3+
2+
1+
2+
0+0+
2+
4+
3+
Surgery (N=80)
2+
4+
3+
3+ 3+
2+
2+
1+1+
4+
3+
81% 82%
Baseline 1 Year
0+
Baseline 1 Year
99% 98%
1+
N=149
Baseline 5 Years
N=106
p < 0.005 p < 0.005 p < 0.005 p < 0.005
N=66
Baseline 5 Years
N=41
N = survivors with paired data; p-values for descriptive purposes only PML04247 Rev. AMitral Regurgitation Grade
EVEREST II RCT All Treated Patients (N=258)
MitraClip (N=178) Surgery (N=80)
INSUFIENCIA MITRAL
10. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Final Results of the EVEREST
Controlled Trial of Percutane
Reduction of Mitral Reg
Ted Feldman, MD, FACC, F
on behalf of the EVEREST II I
ACC 2014
Washington, DC
NYHA Functional Class
EVEREST II RCT All Treated Patients (N=258)
MitraClip (N=178)
NYHA I/II at 1 and 5 Years
I I
I V
I I I
I I I
I I
I I
I
I
I I
I V
I I I
Surgery (N=80)
NYHA I/II at 1 and 5 Years
I I
I V
I I I
I I I
I I
I I
I
I
I I
I V
I I I
98% 91% 88% 98%
I I
I I
p < 0.005 p < 0.005 p < 0.005 p < 0.005
Baseline 1 Year
N=151
Baseline 5 Years
N=106
Baseline 1 Year
N=66
Baseline 5 Years
N=42
N = survivors with paired data; p-values for descriptive purposes only PML04247 Rev. ANYHA Functional Class
EVEREST II RCT All Treated Patients (N=258)
MitraClip (N=178) Surgery (N=80)
INSUFIENCIA MITRAL
15. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
...........................................................................................................................................................
...........................................................................................................................................................
sPapoutsis,Steffen Schneider,Armin W elz,and Friedrich W .Mohr,for the
utive Board
y, Medical Clinic I,Kerckhoff Heart and Thorax Center, University of Giessen, Benekestrasse. 2-8, Bad Nauheim 61231,Germany
sed 5 August 2013;accepted 22 August 2013
Aorticstenosisisafrequent valvular diseaseespeciallyinelderlypatients.Catheter-basedvalveimplantationhasemerged
asavaluabletreatment approachfor thesepatientsbeingeither at veryhighriskfor conventional surgeryor evendeemed
inoperable.TheGermanAorticValveRegistry(GARY) providesdataonconventional andcatheter-based aorticproce-
dureson an all-comersbasis.
A total of13860consecutivepatientsundergoingrepair for aorticvalvedisease[conventional surgeryandtransvascular
(TV) or transapical (TA) catheter-basedtechniques] havebeenenrolledinthisregistryduring2011andbaseline,proced-
ural,andoutcomedatahavebeenacquired.Theregistrysummarizestheresultsof6523conventional aorticvalverepla-
cementswithout (AVR)and3464withconcomitant coronarybypasssurgery(AVR+ CABG)aswellas2695TVAVIand
1181 TA interventions(TA AVI).Patientsundergoingcatheter-based techniquesweresignificantly older andhadhigher
risk profiles.Thestrokeratewaslow inall groupswith1.3%(AVR),1.9%(AVR+ CABG),1.7%(TVAVI),and 2.3%(TA
AVI).Thein-hospital mortality was2.1%(AVR) and4.5%(AVR+ CABG) for patientsundergoingconventional surgery,
and 5.1%(TVAVI) and AVI 7.7%(TA AVI).
Thein-hospital outcomeresultsof thisregistryshow that conventional surgery yieldsexcellent resultsinall risk groups
and that catheter-based aortic valve replacements is an alternative to conventional surgery in high risk and elderly
patients.
------------------------------------------------------------------------------------------------------------------------------------
Aortic stenosis † Surgery † Catheter-based valvereplacement † GARY
.....................................................................................................................................................................................
.....................................................................................................................................................................................
CLIN ICAL RESEARCH
The German Aortic Valve Registry
(GARY): in-hospital outcome
Christian W . Hamm*, Helge Mo¨llmann, David Holzhey, Andreas Beckmann,
Christof Veit, Hans-Reiner Figulla, J. Cremer, Karl-Heinz Kuck, Ru¨diger Lange,
Ralf Zahn, Stefan Sack, Gerhard Schuler, Thomas W alther, Friedhelm Beyersdorf,
Michael Bo¨hm, Gerd Heusch, Anne-Kathrin Funkat, Thomas Meinertz, Till Neumann,
KonstantinosPapoutsis, Steffen Schneider, Armin W elz, and Friedrich W . Mohr, for the
GARY-Executive Board
Department of Cardiology, Medical Clinic I, Kerckhoff Heart and Thorax Center, University of Giessen, Benekestrasse. 2-8, Bad Nauheim 61231, Germany
Received 24 May2013; revised 5 August 2013; accepted 22 August 2013
Back gr ound Aorticstenosisisafrequent valvular diseaseespeciallyinelderlypatients.Catheter-basedvalveimplantationhasemerged
asavaluabletreatment approachfor thesepatientsbeingeither at veryhighrisk for conventional surgeryor evendeemed
inoperable.TheGerman Aortic ValveRegistry (GARY) providesdataonconventional and catheter-based aortic proce-
dureson an all-comers basis.
Met hods and
r esult s
A total of 13 860consecutive patientsundergoingrepair for aortic valvedisease[conventional surgery and transvascular
(TV) or transapical (TA) catheter-based techniques] havebeenenrolledinthisregistryduring2011andbaseline,proced-
ural,and outcomedatahavebeen acquired.Theregistry summarizestheresultsof 6523 conventional aortic valverepla-
cementswithout (AVR) and3464withconcomitant coronarybypasssurgery(AVR+ CABG) aswell as2695TVAVIand
1181 TA interventions(TA AVI). Patientsundergoingcatheter-based techniquesweresignificantly older and had higher
risk profiles. The strokeratewaslow in all groupswith 1.3%(AVR), 1.9%(AVR+ CABG), 1.7%(TVAVI), and 2.3%(TA
AVI).Thein-hospital mortality was2.1%(AVR) and 4.5%(AVR+ CABG) for patientsundergoingconventional surgery,
and 5.1%(TVAVI) and AVI 7.7%(TA AVI).
Conclusion The in-hospital outcome resultsof thisregistry show that conventional surgery yieldsexcellent resultsin all risk groups
and that catheter-based aortic valve replacements is an alternative to conventional surgery in high risk and elderly
patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywor ds Aortic stenosis † Surgery † Catheter-based valve replacement † GARY
Introduction
Aortic stenosis is the most frequent type of valvular heart disease
in the Western Countries and presents mostly in an advanced age
as a calcific form. The prognosis is poor once the patient becomes
symptomatic. Surgical valve replacement isthe established standard
management, which alleviates symptoms and improves survival.1
Valvuloplasty of the stenosed valve hasbeen over many yearsapal-
liative option for the short term for highly selected, inoperable
patients. Recently, catheter-based valve implantations have
become an alternative for selected, particularly elderly
patients.2–4
Smaller, randomized studies confirmed acceptable
outcomesinhighriskandinoperablepatients5,6
for thetransvascu-
lar (TV) as well asthe transapical (TA) approach when compared
European Heart Journal
doi:10.1093/eurheartj/eht381
atBibliotecaVirtualdelSistemaSanitarioPúblicodeAndalucÃ-aonMarch17,2014http://eurheartj.oxfordjournals.org/Downloadedfrom
TAVI
CLINICAL RESEEuropeanHeart Journal
doi:10.1093/eurheartj/eht381
European Heart Journal Advance Access published September 10, 2013
16. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
.....................................................................................................................................................................................
.....................................................................................................................................................................................
The German Aortic Valve Registry
(GARY): in-hospital outcome
Christian W . Hamm*, Helge Mo¨llmann, David Holzhey, AndreasBeckmann,
Christof Veit, Hans-Reiner Figulla, J. Cremer, Karl-Heinz Kuck, Ru¨diger Lange,
Ralf Zahn, Stefan Sack, Gerhard Schuler, ThomasW alther, Friedhelm Beyersdorf,
Michael Bo¨hm, Gerd Heusch, Anne-Kathrin Funkat, ThomasMeinertz, Till Neumann,
KonstantinosPapoutsis,Steffen Schneider,Armin W elz,and Friedrich W .Mohr,for the
GARY-Executive Board
Department of Cardiology, Medical Clinic I, Kerckhoff Heart and Thorax Center, University of Giessen, Benekestrasse. 2-8, Bad Nauheim 61231,Germany
Received24 May2013;revised 5 August 2013;accepted 22 August 2013
Background Aorticstenosisisafrequent valvular diseaseespeciallyinelderlypatients.Catheter-basedvalveimplantationhasemerged
asavaluabletreatment approachfor thesepatientsbeingeither at veryhighriskfor conventional surgeryor evendeemed
inoperable.TheGermanAorticValveRegistry(GARY) providesdataonconventional andcatheter-based aorticproce-
dureson an all-comersbasis.
Met hods and
result s
A total of13860consecutivepatientsundergoingrepair for aorticvalvedisease[conventional surgeryandtransvascular
(TV) or transapical (TA) catheter-based techniques] havebeenenrolledinthisregistryduring2011andbaseline,proced-
ural,andoutcomedatahavebeenacquired.Theregistrysummarizestheresultsof 6523conventional aorticvalverepla-
cementswithout (AVR) and3464withconcomitant coronarybypasssurgery(AVR+ CABG) aswellas2695TVAVIand
1181TA interventions(TA AVI).Patientsundergoingcatheter-based techniquesweresignificantly older and had higher
risk profiles.Thestrokeratewaslow inall groupswith 1.3%(AVR),1.9%(AVR+ CABG),1.7%(TVAVI),and 2.3%(TA
AVI).Thein-hospital mortality was2.1%(AVR) and4.5%(AVR+ CABG) for patientsundergoingconventional surgery,
and 5.1%(TVAVI) and AVI 7.7%(TA AVI).
Conclusion Thein-hospital outcomeresultsof thisregistry show that conventional surgery yieldsexcellent resultsin all risk groups
and that catheter-based aortic valve replacements is an alternative to conventional surgery in high risk and elderly
patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Aortic stenosis † Surgery † Catheter-based valvereplacement † GARY
Introduction
Aortic stenosis is the most frequent type of valvular heart disease
in the Western Countries and presents mostly in an advanced age
Valvuloplasty of the stenosed valvehasbeen over many yearsapal-
liative option for the short term for highly selected, inoperable
patients. Recently, catheter-based valve implantations have
become an alternative for selected, particularly elderly
European Heart Journal
doi:10.1093/eurheartj/eht381
atBibliotecaVirtualdelSistemaSanitarioPúblicodeAndalucÃ-aonMarch17,2014http://eurheartj.oxfordjournals.org/Downloadedfrom
TAVI
CLINICAL RESEAEuropeanHeart Journal
doi:10.1093/eurheartj/eht381
European Heart Journal Advance Access published September 10, 2013
18. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
.....................................................................................................................................................................................
.....................................................................................................................................................................................
CLIN ICA L RESA RCH
TAVI
Advanced chronic kidney disease in pat ient s
undergoing t ranscat het er aort ic valve
implant at ion: insight s on clinical out comes and
prognost ic markersfrom a large cohort of pat ient s
Ricar do A llende1†, John G. W ebb2, A nt onio J. Munoz-Gar cia3, Pet er de Jaeger e4,
Cor r ado T am bur ino5, A nt onio E. Dager 6, A sim Cheem a7, Vicenc¸ Ser r a8,
Ignacio A m at -Sant os9, Jam es L. Velianou10, Mar co Bar bant i2, Danny Dvir 2,
Juan H . A lonso-Br iales3, Rut ger -Jan N uis4, Elham ula Faqir i 4, Sebast iano Im m e5,
Luis Miguel Benit ez6, A ngela Mar ia Cucalon6, H at im A l Lawat i7,
Br uno Gar cia del Blanco8, Javier Lopez9, Madhu K. N at ar ajan10,
Rober t DeLar ochellie`r e1, Mar ina U r ena1, H enr ique B. Ribeir o1, Er ic Dum ont 1,
Luis N om bela-Fr anco 1†, and Josep Rode´s-Cabau1*
1
Quebec Heart and LungInstitute, Laval University, Quebec city,QC,Canada; 2
St Paul’sHospital,University of British Columbia, Vancouver,BC,Canada; 3
Hospital Universitario Virgen de
la Victoria, Malaga, Spain; 4
Thoraxcenter-Erasmus MC, Rotterdam, The Netherlands; 5
Ferrarotto Hospital, University of Catania, Catania, Italy; 6
Angiografia de Occidente S.A., Cali,
Colombia; 7
St-Michael’sHospital, Toronto, ON, Canada; 8
Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 9
Hospital Clinico Universitario de Valladolid, Valladolid, Spain;
and 10
Hamilton General Hospital, Hamilton, ON, Canada
Received 11 August 2013; revised 9 February 2014; accepted 3 April 2014
A im Theaimofthisstudywasto determinetheeffectsofadvancedchronickidneydisease(CKD) onearlyandlateoutcomesafter
transcatheter aortic valve implantation (TAVI), and to evaluate the predictive factorsof poorer outcomesin such patients.
M et hods
and r esult s
This was a multicentre study including a total of 2075 consecutive patients who had undergone TAVI. Patients were
grouped according the estimated glomerular filtration rate as follows: CKD stage 1-2 (≥ 60 mL/min/1.73 m2
;
n ¼ 950), stage 3 (30–59 mL/min/1.73 m2
; n ¼ 924), stage 4 (15–29 mL/min/1.73 m2
; n ¼ 134) and stage 5 (, 15 mL/
min/1.73 m2
or dialysis; n ¼ 67). Clinical outcomes were evaluated at 30-days and at follow-up (median of 15 [6–29]
months) and defined according to the VARC criteria. Advanced CKD (stage 4–5) was an independent predictor of
30-day major/life-thr eatening bleeding (P¼ 0.001) and mortality (P¼ 0.027), and late overall, cardiovascular and non-
cardiovascular mortality (P, 0.01 for all).Pre-existingatrial fibrillation (HR:2.29,95%CI:1.47–3.58,P¼ 0.001) and dia-
lysistherapy (HR: 1.86, 95%CI: 1.17–2.97, P¼ 0.009) were the predictorsof mortality in advanced CKD patients, with a
mortality rate ashigh as71%at 1-year follow-up in those patientswith these 2 factors. Advanced CKD patientswho had
survived at 1-year follow-up exhibited both asignificant improvement in NYHA class(P, 0.001) and no deterioration in
valve hemodynamics (P¼ NSfor changes in mean gradient and valve area over time).
Conclusions Advanced CKD wasassociated withahigher rateof earlyand latemortalityand bleedingeventsfollowingTAVI,withAFand
dialysistherapydeterminingahigher risk inthesepatients.Themortality rateof patientswith both factorswasunacceptably
high and thisshould be taken into account in the clinical decision-makingprocessin thischallenginggroup of patients.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
K eyw o r ds Chronic kidney disease † Dialysis † Transcatheter aortic valve implantation † Atrial fibrillation
* Corresponding author. Tel: + 1 4186568711, Fax:+ 1 4186564544, Email: josep.rodes@criucpq.ulaval.ca
†
R.A. and L.N.-F. have equally contributed to this work.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2014. For permissions please email: journals.per missions@oup.com.
European Heart Journal
doi:10.1093/eurheartj/ehu175
atBibliotecaVirtualdelSistemaSanitarioPúblicodeAndalucÃ-aonJune4,2014http://eurheartj.oxfordjournals.org/Downloadedfrom
...........................................................................................................................................................
...........................................................................................................................................................
arochellie`re1, Marina Urena1, Henrique B. Ribeiro1, Eric Dumont1,
la-Franco1†
, and Josep Rode´s-Cabau1*
stitute,Laval University,Quebeccity,QC,Canada;2
St Paul’sHospital,UniversityofBritishColumbia,Vancouver,BC,Canada;3
Hospital Universitario Virgende
Thoraxcenter-Erasmus MC, Rotterdam, The Netherlands;5
Ferrarotto Hospital,University of Catania, Catania, Italy; 6
Angiografiade Occidente S.A., Cali,
ospital, Toronto, ON,Canada; 8
Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 9
Hospital Clinico Universitario deValladolid, Valladolid, Spain;
ospital, Hamilton, ON, Canada
evised 9 February2014;accepted 3 April 2014
Theaimofthisstudywastodeterminetheeffectsofadvancedchronickidneydisease(CKD)onearlyandlateoutcomesafter
transcatheter aorticvalveimplantation(TAVI),andto evaluatethepredictivefactorsof poorer outcomesinsuchpatients.
This was a multicentre study including a total of 2075 consecutive patients who had undergone TAVI. Patients were
grouped according the estimated glomerular filtration rate as follows: CKD stage 1-2 (≥ 60 mL/min/1.73 m2
;
n ¼ 950), stage 3 (30–59 mL/min/1.73 m2
; n¼ 924), stage 4 (15–29 mL/min/1.73 m2
;n¼ 134) and stage 5 (, 15 mL/
min/1.73 m2
or dialysis; n ¼ 67). Clinical outcomes were evaluated at 30-daysand at follow-up (median of 15 [6–29]
months) and defined according to the VARC criteria. Advanced CKD (stage 4–5) was an independent predictor of
30-day major/life-threateningbleeding(P¼ 0.001) and mortality (P¼ 0.027), and late overall, cardiovascular and non-
cardiovascular mortality(P, 0.01for all).Pre-existingatrial fibrillation(HR:2.29,95%CI:1.47–3.58,P¼ 0.001) anddia-
lysistherapy(HR:1.86,95%CI:1.17–2.97,P¼ 0.009) werethepredictorsofmortalityinadvanced CKD patients,witha
mortality rateashighas71%at 1-year follow-upinthosepatientswiththese2factors.Advanced CKD patientswho had
survivedat 1-year follow-upexhibited bothasignificant improvement inNYHA class(P, 0.001) andno deteriorationin
valve hemodynamics (P¼ NSfor changesin mean gradient and valveareaover time).
AdvancedCKD wasassociatedwithahigher rateofearlyandlatemortalityandbleedingeventsfollowingTAVI,withAFand
dialysistherapydeterminingahigher riskinthesepatients.Themortalityrateofpatientswithbothfactorswasunacceptably
highand thisshould betaken into account in theclinical decision-makingprocessin thischallenginggroup of patients.
CLINICAL REuropean Heart Journal
doi:10.1093/eurheartj/ehu175
European Heart Journal Advance Access published May 5, 2014
CLINICAL REEuropeanHeart Journal
doi:10.1093/eurheartj/ehu175
European Heart Journal Advance Access published May 5, 2014
TAVI
21. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Análisis post-hoc no aleatorizado
Pacientes incluidos desde 2007 a 2012 (Edwards sólo desde 2010)
Sesgos (preferencias de operador, curva de aprendizaje, patrón de
calcificación anular) no corregidos pese a “propensity matching”
Superviviencia al año al año similar (88% ES, 84% MCV, p= 0,42)
No diferencias en otros estudios (FRANCE 2, UK TAVI, PRAGMATIC..)
Descenso de la “more-then-mild” IAO con el tiempo con la Corevalve
(11,5% a 30 días y 4,1% al año en en US Pivotal Trial)
TAVI
Selección del tamaño de dispositivo heterogénea con pocos casos con TAC
24. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
Aunque la válvula balón expandible tiene mas tasa de éxito que la autoexpandible
no hay datos de que esto tenga impacto en el seguimiento (muerte, ACV, calidad de vida)
IAO ≥ 2 e implante de una segunda válvula fueron mayores con la válvula autoexpandible,
mientras que los ACV y la oclusión coronaria fueron numerica, aunque no estadisticamente,
mayores con la balón expandible
Datos recientes sugieren que la IAO disminuye en el seguimiento de la válvula
autoexpandible
La experiencia del operador es un factor crucial en el éxito del procedimiento, y debe
ser tenido en cuenta en la selección del tipo de válvula
En espera de resultados a un año
TAVI
30. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
6Extreme Risk Study | Iliofemoral PivotalPopma JACC 2014 March 19 (epub ahead of print)
On behalf of the US CoreValve Investigators
Paravalvular Regurgitation
23Extreme Risk Study | Iliofemoral PivotalTCT 2013 LBCT (JACC 2014)
TAVI
34. TAVIFOP INSUFICIENCIA MITRALDENERVACIÓN RENAL
LIMITACIONES
Se incluyen características preprocedimiento, no complicaciones intra o
Post procedimiento, que pueden incrementar la mortalidad
No tiene validación externa
FRANCE 2 no recogió datos de la capacidad cognitiva ni fragilidad
TAVI